SAMSUNG PHARM. Co., LTD. (KRX:001360)
South Korea · Delayed Price · Currency is KRW 1,680.00
+39.00 (2.38%)
At close: Sep 8, 2025
SAMSUNG PHARM. Co., LTD. Revenue
In the year 2024, SAMSUNG PHARM. Co., LTD. had annual revenue of 44.29B KRW, down -14.75%. SAMSUNG PHARM. Co., LTD. had revenue of 23.34B in the quarter ending September 30, 2019, with 122.70% growth.
Revenue
44.29B
Revenue Growth
-1.90%
P/S Ratio
3.57
Revenue / Employee
184.56M
Employees
240
Market Cap
158.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | -7.66B | -14.75% |
| Dec 31, 2023 | 51.96B | 5.47B | 11.77% |
| Dec 31, 2018 | 46.48B | 4.56B | 10.89% |
| Dec 31, 2017 | 41.92B | -5.27B | -11.18% |
| Dec 31, 2016 | 47.19B | 5.03B | 11.93% |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |